London close: Footsie struggles to hold on to gains after jobs data
2nd Nov 2012 16:42
- US jobs provide temporary boost, but gains trimmed - Data unlikely to change Fed's stance, says analyst - Financials Admiral and RBS disappoint While the closely-watched US jobs report provided a bit of a bounce in early afternoon trade, the Footsie had pared gains to finish flat by the close as
Read moreFTSE 250 movers: Shares in Bumi rocket on proposal news
2nd Nov 2012 16:23
Mining group Bumi advanced after saying it has appointed Rothschild Goup as its financial adviser with immediate effect to evaluate the proposal received from Long Haul Holdings. Shares in Dixons rose once again, boosted by the news that its main High Street rival, Comet, is likely to go into admi
Read moreLondon midday: Markets cautious ahead of US non-farm payrolls
2nd Nov 2012 11:30
- All eyes on US jobs data - Outcome could be a major factor in presidential elections - Admiral, Meggitt and RBS disappoint The FTSE 100 was little changed by Friday lunchtime, having trade within a narrow range for most of the morning session, with investors nervous ahead the pivotal employment
Read moreHikma to suspend production in New Jersey
2nd Nov 2012 07:29
Hikma Pharmaceuticals is considering the future of its Generics business as its Eatontown facility in New Jersey continues to be dogged by compliance issues. The group has opted to halt commercial production of generic drugs at Eatontown facility in the US until mid-January while it gets to grips
Read moreWednesday broker round-up
24th Oct 2012 09:25
African Barrick Gold: Investec raises target from 485p to 530p, hold rating kept. Aggreko: Seymour Pierce maintains buy rating and 2,500p target. AstraZeneca: Panmure Gordon keeps hold rating and 3,000p target. British American Tobacco: Jefferies keeps buy rating and 3,730p target; Panmure Gordon
Read moreBroker tips: RBS, Weir, Aggreko...
22nd Oct 2012 12:45
Shares in part-nationalised lender Royal Bank of Scotland (RBS) are trading at 0.6 times tangible net asset value (tNAV) and close to a new 17-month high, which has prompted broker Investec to downgrade its rating for the stock from 'hold' to 'sell'. Investec forecasts another "jaw-dropping statuto
Read moreBroker snap: UBS downgrades Hikma to 'sell'
22nd Oct 2012 12:43
UBS has cut its recommendation for pharmaceuticals group Hikma from 'neutral' to 'sell', saying that the market is pricing in a 'blue sky scenario'. The broker said that it is hard to justify Hikma's valuation "as we believe that the market is pricing a blue sky scenario with the US Injectables sup
Read moreHikma signs agreement for marketing of anti-cancer compound
22nd Oct 2012 12:26
FTSE 250 group Hikma Pharmaceuticals has signed an agreement for the registration and marketing of Lutrate 1 month, GP Pharm's anti-cancer compound, for the Middle East and North Africa (MENA) region. Lutrate 1 month is a hormonal androgen deprivation therapy used to prevent tumor growth in patien
Read moreMonday broker round-up - UPDATE
22nd Oct 2012 08:19
888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl
Read moreLondon close: Markets nervous ahead of Jackson Hole
29th Aug 2012 16:39
- Stocks look to Jackson Hole summit for a boost - Draghi hints at action ahead of ECB meeting - Glencore leads fallers on growing opposition to merger Global stock markets were mostly trading in the red on Wednesday afternoon in spite an upwards revision to US economic growth as investors showed c
Read moreLondon midday: Markets look to Jackson Hole for boost
29th Aug 2012 11:37
- Greece agrees on budget plan - Spain a concern as Catalonia in need of aid - Markets look ahead to Jackson Hole meeting The Footsie remained firmly in the red in morning trade as concerns over the Eurozone and speculation about the upcoming Jackson Hole meeting in Wyoming continue to be the focus
Read moreLondon open: Glencore leads fallers early on
29th Aug 2012 08:25
- Spain a concern as Catalonia needs aid - Markets await Bernanke - Ex-div Glencore a heavy faller early on Ex-div stocks and miners were weighing heavily on the FTSE 100 index in early trading on Wednesday morning with worries about Spain weighing on sentiment. It was revealed yesterday that the
Read moreMonday broker round-up -UPDATE
20th Aug 2012 08:17
AstraZeneca: JPMorgan Cazenove downgrades to underweight, target lifted from 2,800p to 2,970p. Balfour Beatty: JPMorgan Cazenove downgrades to neutral. Barclays: Citigroup reiterates buy and 330p target price. ENRC: Credit Suisse downgrades to neutral, target cut from 500p to 450p. FirstGroup: J
Read moreFriday tips round-up: Hikma, African Barrick, Lenovo
17th Aug 2012 06:58
What a difference a year makes, Tempus in The Times proclaims. When the Arab Spring was in full flow, investors worried that Hikma Pharmaceuticals was too exposed to the unstable region. The company, based in Jordan, almost halved last year's sales growth forecast as governments fell. Now it looks w
Read moreBroker tips: ENRC, Hikma, Micro Focus
16th Aug 2012 12:10
UBS has cut its target price for mining group Eurasian Natural Resources Corp (ENRC) from 585p to 565p after first-quarter figures came in below expectations. UBS has reduced its 2012 and 2013 EPS estimates by 4% and 7%, respectively, mainly on the back of a higher tax rate (which moderates from 20
Read more